Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open-label, Three-arm, Parallel, Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole Versus Letrozole or Vinorelbine Alone in Post-menopausal Women With Hormone Receptor-positive HER2-negative Early Breast Cancer

NCT02802748 is registered in ClinicalTrials.gov with SOLTI Breast Cancer Research Group as lead sponsor.

NCT NCT02802748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02802748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open-label, Three-arm, Parallel, Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole Versus Letrozole or Vinorelbine Alone in Post-menopausal Women With Hormone Receptor-positive HER2-negative Early Breast Cancer
Lead sponsor
SOLTI Breast Cancer Research Group
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2016
Completion date
January 31, 2018
Enrollment
60 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer